Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Glioblastoma 77Brain Neoplasms 75Glioma 68Astrocytoma 30Central Nervous System Neoplasms 24Gliosarcoma 21Neuroblastoma 19Lung Neoplasms 19Ependymoma 19Medulloblastoma 18Oligodendroglioma 17Meningioma 16Breast Neoplasms 15Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 10Sarcoma 7Neuroendocrine Tumors 7Neuroectodermal Tumors, Primitive, Peripheral 7Melanoma 7Glioma, Subependymal 7Ganglioneuroblastoma 7Wilms Tumor 6Thyroid Neoplasms 6Rhabdoid Tumor 6Osteosarcoma 6Neuroectodermal Tumors, Primitive 6Meningeal Carcinomatosis 6Lymphoma, Non-Hodgkin 6Lymphoma 6Histiocytosis, Langerhans-Cell 6

Interventions

vatalanib 1Trabectedin 1Magnetic Resonance Spectroscopy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiopericytoma, Malignant × Magnetic Resonance Spectroscopy × CNS × Clear all
NCT00492089 2014-05-09

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
11 enrolled 7 charts
CNSHead & Neck

Hemangiopericytoma, Malignant, Squamous Cell Carcinoma of Head and Neck, Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Radiation Injuries, Salivary Gland Neoplasms, Choroid Plexus Neoplasms, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡